Samsung Biologics Partners with European Pharmaceutical Firm for Significant Manufacturing Agreement

Samsung Biologics, a leading global contract development and manufacturing organization (CDMO), recently revealed it has forged a collaboration with a European pharmaceutical company, although the identity of this partner remains undisclosed. The collaborative effort involves a series of manufacturing agreements totaling more than 8 million, with services set to extend through the end of December 2031.

“We are delighted to broaden our collaboration with the European pharmaceutical company towards our mutual objective of delivering top-notch biopharmaceuticals to patients,” remarked John Rim, President and CEO of Samsung Biologics, in an official statement.

Rim further emphasized the company’s commitment to expanding strategic collaborations globally, alongside ongoing investments in manufacturing technologies and capabilities. “Our aim is to offer the highest quality services across all stages and to strengthen our trusted partnerships,” he added.

This recent development adds to a series of agreements Samsung Biologics established throughout the United States, Asia, and Europe in the past year, increasing its total contract value to over billion.

For instance, in October 2024, Samsung Biologics secured a significant manufacturing deal valued at .24 billion with a pharmaceutical company based in Asia.

Looking ahead, Samsung Biologics is set to enhance its offerings with antibody-drug conjugate (ADC) services by the close of 2024, with plans for a specialized manufacturing facility to be established shortly. In February 2024, the company entered into a partnership with South Korean biotech firm LegoChem Biosciences to advance the production of LegoChem’s ADC candidate aimed at treating solid tumors.

Samsung Biologics is also preparing for the launch of Plant 5, marking the first facility within its second Bio Campus, anticipated to be operational by April 2025. This new plant, covering an area of 96,000m², will feature a capacity of 180,000 liters. By next year, Bio Campus II is expected to be functional, incorporating additional large-scale manufacturing plants and an open innovation hub. The entire endeavor, which initiated with a land acquisition of 360,000m² in July 2022, carries an estimated cost of nearly .4 billion.

“In light of the ongoing surge in the demand for outsourced biopharmaceutical manufacturing, we are proactively pursuing this investment to align with our growth strategy, thereby reinforcing our status as a prominent CDMO,” Rim noted in a press release. “The new facility will empower us to deliver even greater innovations and services, enhancing speed to market and flexibility for our clients.”